Nasdaq
$1.53▼ 0.33%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $407.2MShares out 2.700M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
22- 9.23Pre-market26.09.23 13:15filedEFFECTOther#●●●#●●●
Autolus Therapeutics plc
The registration statement (Form F-3) filed by Autolus Therapeutics plc was declared effective by the SEC on September 22, 2026. This effectiveness allows the company to issue securities and raise capital as needed in the future.…more
$1.53-0.33%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.22After-hours26.09.23 05:51424B3Offering
Autolus Therapeutics plc
Autolus Therapeutics is registering the resale of up to 3,500,000 ADSs issuable upon the exercise of a warrant held by Perceptive Credit Holdings V, LP to fulfill contractual obligations. The selling securityholder will receive all proceeds from the sale, and the company will not receive any proceeds from the offering, other than the warrant exercise price of $1.9314 per ADS if exercised for cash.…more
$1.53-0.33%vs prev closeView filingShare - 9.15After-hours26.09.16 05:22DEL AMOther
Autolus Therapeutics plc
Autolus Therapeutics plc has filed a delaying amendment for its Form S-3 registration statement, which was originally submitted on September 14, 2026. This filing formally postpones the effective date of the registration statement until the company submits a further amendment to finalize its effectiveness.…more
$1.53-0.33%vs prev closeView filingShare
21 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.5Pre-market26.10.05 21:34#●●●#●●●
Autolus Therapeutics to Present Lupus Clinical Data at ACR Convergence 2026…more
Autolus Therapeutics announced that it will present updated data from its Phase 1 CARLYSLE trial for severe refractory systemic lupus erythematosus. The findings are scheduled to be showcased in a poster presentation on November 10 at the ACR Convergence 2026 meeting.…more
$1.53-0.33%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.9Pre-market26.09.09 20:00
●●●●●●●● ●●●●● ●●●●●●
Autolus Therapeutics has been granted FDA Regenerative Medicine Advanced Therapy (RMAT) designation for its obe-cel candidate to treat systemic lupus erythematosus and lupus nephritis. This status aims to accelerate development and regulatory review, though clinical progress remains ongoing.…more
$1.53-0.33%vs prev close - 8.11Pre-market26.08.11 20:00
●●●●●●●● ●●●●● ●●●●●●
Autolus는 주력 제품 AUCATZYL의 판매 호조로 2분기 매출이 전년 대비 119% 급증하며 연간 매출 가이던스를 상향 조정했습니다. 또한 신규 자금 조달을 통해 운영 자금을 확보하고 파이프라인 임상 개발을 차질 없이 진행 중입니다.…more
$1.53-0.33%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report